Skip to main content
. Author manuscript; available in PMC: 2012 Feb 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2010 Jul 27;38(2):358–377. doi: 10.1007/s00259-010-1569-z

Fig. 3.

Fig. 3

a 18F-FDG uptake is seen in the primary lesion and multiple lymph nodes. b 14 days after treatment with an EGFR inhibitor shows significant reduction in PET activity, corresponding with a 62% reduction in SUV at previous disease sites. Reprinted with permission from the Society of Nuclear Medicine [50]